ARMMs: a new solution for therapeutic delivery
Many novel therapeutics are constrained by delivery challenges. Vehicles such as viral vectors and lipid nanoparticles have issues with biodistribution, loading capacity, immunogenicity, dose-limiting toxicity, and manufacturing.
Vesigen is engineering a non-viral technology platform to deliver RNA, proteins, and gene-editing complexes to specific tissues and cell types—including those that have been hard to target. Our technology is based on a distinct class of human extracellular vesicles called ARMMs (ARRDC1-Mediated Microvesicles), which mediate intercellular and inter-tissue signaling.
